BlossomHill Therapeutics Announces $84 Million Financing to Accelerate Clinical-Stage Pipeline Including OMNI-EGFR Inhibitor for NSCLC
“With clinical data beginning to come into focus across both of our lead programs, momentum is building at BlossomHill Therapeutics,” said J. Jean Cui, Ph.D., President & Chief Executive Officer of BlossomHill. “We are delighted by the strong vote of confidence from new and existing investors in this financing, which arrives at a critical juncture as we drive our clinical programs forward and leverage our established track record in oncology drug design to address the challenges of cancer treatment resistance and deliver meaningful benefit for cancer patients.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.